AstraZeneca announces a $2.5 billion investment in Beijing to establish a new R&D center, aiming to enhance its global research capabilities and strengthen its commitment to China'...
AstraZeneca announces a $2.5 billion investment to establish a strategic R&D center in Beijing, marking its second in China and sixth worldwide. This move highlights the company's ...
AstraZeneca announces a $2.5 billion investment to establish its second R&D center in Beijing, aiming to employ 1,700 personnel. The initiative includes partnerships with Beijing's...
AstraZeneca announces a $1 billion acquisition of EsoBiotec SA, aiming to enhance its biotech portfolio and advance innovative cell therapies globally. The deal, expected to close ...
AstraZeneca plc has announced a definitive agreement to acquire EsoBiotec SA for up to $1 billion, aiming to advance innovative drug development and expand its biotech presence. Th...
AstraZeneca has scrapped plans for a vaccine plant near Liverpool after failing to agree on government funding. The move highlights challenges in UK's vaccine production ambitions,...
AstraZeneca and Daiichi Sankyo withdraw their EU marketing authorization application for datopotamab deruxtecan due to mixed trial results, but remain committed to ongoing research...
